

# **PTABLE OF CONTENTS**

- 1. Key investment highlights	p. 3
- 2. Strategy	p. 4
- 3. Strong track record	p. 5
- 4. Use of proceeds	p. 6
- 4.1. Acquisitions	p. 8
- 4.2. Investment pipeline	p. 9
- 5. Key financials	p. 15
- 6. Transaction details	p. 16
- 7. Outlook	p. 18
- 8. Q&A	p. 19
- Appendix	p. 20

# 91. KEY INVESTMENT HIGHLIGHTS

#### **Leading listed Belgian REIT with 110 employees**

Market cap €1.9 billion & ample liquidity Member of BEL20 EPRA Europe GPR 250 Sustainable dividend yield 5% & 2015 dividend target €5.50/share

### Moderate risk profile, sustainability of earnings and diversified sources of funding

Diversified portfolio €3.2 billion

Major healthcare investor in Continental Europe (40% of portfolio)

Average lease duration 11 years & occupancy rate 95.2%

Complementarity of property segments

Diversified sources of funding & 2015 cost of debt <3%

Major
office investor
in Brussels
(41% of portfolio)



# <sup>9</sup>2. STRATEGY

## **Strategic focus**

## **Healthcare properties**

- Acquisitions in new markets
   (namely the Netherlands & Germany)
- Greenfield projects in more mature markets (Belgium and France)
- Further diversification per country, per medical specialty and per operator

# Office properties in Belgium

- Maintain a critical size
- Focus on premium quality
- Pro-active asset management
- Renovation and reconversion program
  - Arbitrage

(Disposals if high concentration of risk or if possible realisation of gains)

driven by demography



driven by economic factors

# **Opportunistic investments**

**Property of distribution networks** 

**Public-private partnerships** 



## \*

# 3. GROWTH AMBITION SUPPORTED BY STRONG TRACK RECORD

**Average investments of M€225/year since 1996** 

## 10 years of experience in healthcare real estate:

**Experienced and dedicated healthcare team of 15 FTE** 

Broad offering to healthcare operators: from mere financing to integrated management of development projects

Established networks of 27 operatortenants currently in portfolio In-depth knowledge of the various healthcare sub-segments, in terms of regulatory environment, financing and competition


Over 50 healthcare projects managed or overseen over the past 10 years (greenfield projects, renovations, extensions, reconversions)

#### **Active prospection:**

in Belgium since 2005, in France since 2008, in the Netherlands since 2011 and in Germany since 2013



# 4. USE OF PROCEEDS






# 4. USE OF PROCEEDS (CONT'D)

Segment	Breakdown of portfolio at 31.12.2014	2015-2017 Committed pipeline (in M€)	2015-2017 potential scenario: Uncommitted acquisitions (in M€)	2015-2017 potential scenario: Uncommitted disposals (in M€)	Breakdown of portfolio at 31.12.2017
Healthcare real estate	40%	69.0	500.0	-50.0	47%
Offices of which:	41%	172.0	100.0	-200.0	36%
Refurbishment		122.0			
Reconversion		50.0			
Others	19%	9.6	/	/	17%
Total	100%	250.6	600.0	-250.0	100%



# 4.1. USE OF PROCEEDS: ACQUISITIONS


Cofinimmo intends to reinforce its position as major player in Continental Europe in healthcare real estate



**Targeted initial yield > 5.5%** 



# <sup>©</sup> 4.2. USE OF PROCEEDS: M€250 INVESTMENT PIPELINE



- Breakdown of M€250 investment pipeline (2015-2017):
- Renovation of offices buildings: M€122
- Reconversion of office buildings in other usage: M€50
- Healthcare real estate: M€69
- Property of distribution networks: M€10
- Contribution of these investments to rental income:
- 2015: M€1.8
- 2016: M€5.6
- 2017: M€10.5
- Contribution to passing rental income at end 2017: M€16.2/year
- Yield on cost: 6.8%



## OFFICE DEVELOPMENT PROJECTS

### Several offices renovations in Brussels' CBD

#### Belliard 40 (20,000m<sup>2</sup>)

Construction of new building with offices, residential units and retail - M€46

Expected end of works: 2Q2017

Marketing underway

#### Guimard 10-12 (10,800m<sup>2</sup>)

Renovation - M€11

Expected end of works: 3Q2015

Lease signed for 65% of space after works

Marketing of remaining 35% underway

#### **Arts/Kunsten 19H (9,000m²)**

Building to be vacated at end Jan. 2016

Construction of new building - M€23

Expected timing of works: 2Q2016 – 4Q2017





# SOVEREIGN REDEVELOPMENT PROJECT - BRUSSELS DECENTRALISED

#### Axa to vacate site in August 2017

Plot of land Ten Reuken immediately available for residential development:


Approx. 10,000m<sup>2</sup>, i.e. 100 units Construction to be launched in 2016

#### **Future complex:**

Offices or mixed offices/residential
Discussions underway with Brussels Region Planning Administration
Expected redevelopment cost 2018-2020: M€200

Weight in Cofinimmo's total portfolio fair value <3% (before redevelopment costs)







# **OFFICE RECONVERSIONS PROJECTS**

# Office reconversions into other uses, offering better capital returns than renovations as offices

#### Woluwe 34 – Decentralised Brussels (6,700m<sup>2</sup>)

Reconversion of offices to 69 apartments - M€13 Apartments are put up for sale – Price: €3,300/m² Recovered value (sales price – cost of works): €1,300/m² Expected end of works: 1Q2015 – 97% already sold or reserved



#### Woluwe 106-108 – Decentralised Brussels (8,500m<sup>2</sup>)

Reconversion of offices to nursing home – M€13 Signature of a 27 years long lease with operator upon completion of works Planning permission under progress





## PHEALTHCARE DEVELOPMENT PROJECTS

## **Examples of projects in Belgium and France**

#### Noordduin (Koksijde – Belgium)

New construction

- Surface area: 6,440m<sup>2</sup>; Number of beds: 87

- Expected end of works: Q2 2015

Investment: M€9.6Operator: Armonea

#### Suzanna Wesley (Brussels – Belgium)

- New construction

Surface area: 4,900m<sup>2</sup>; Number of beds: 84

Expected end of works: Q4 2015

Investment: M€9.2Operator: Armonea

#### Caux du Littoral (Néville – France)

- Renovation & extension

- Surface area: 3,800m<sup>2</sup>; Number of beds: 60

Expected end of works: Q3 2015

Investment: M€5.2Operator: Handra







## HEALTHCARE DEVELOPMENT PROJECTS

## **Examples of projects in the Netherlands**

#### **Medical office building (Eindhoven)**

New construction Surface: 2.237m<sup>2</sup>

Expected end of works: Q4 2015

Investment: M€4 0

Operator: Stichting Gezondheidscentra Eindhoven



#### Other development projects

5 construction projects to be delivered in 2015 and 2016 Facilities for care of elderly or disabled people or psychiatric care

Investment: M€15.7

Operators: Philadelphia, Martha Flora and Sozorg







# 95. KEY FINANCIALS

### Net current result (excl. IAS 39 impact) – Group share: €6.70 per share

	(in M€)		Per share (in €)	
	31.12.2014	31.12.2013	31.12.2014	31.12.2013
Operating result	177.7	185.6	9.89	10.55
Net current result (excl. IAS 39) - Group share	120.4	119.2	6.70	6.78
IAS 39 impact	-136.1	-14.3	-7.57	-0.82
Net current result - Group share	-15.7	104.9	-0.87	5.96
Result on portfolio	-37.0	-46.2	-2.06	-2.62
Net result - Group share	-52.7	58.7	-2.93	3.34

#### **EPRA financial KPI's**

	31.12.2014	31.12.2013
EPRA Earnings	6.70	6.78
EPRA Net Asset Value (NAV)	96.08	98.85
EPRA Adjusted Net Asset Value (NNNAV)	92.01	95.74
EPRA Net Initial Yield (NIY)	6.06%	6.20%
EPRA Vacancy Rate	4.93%	5.04%
EPRA Cost ratio (cost of vacancy excluded)	15.93%	16.01%



# 96. TRANSACTION DETAILS

**Listing place** 

• Euronext Brussels

**Transaction size** 

Up to M€285.4, represented by 3,004,318 new shares

**Transaction structure** 

- Preferential subscription rights for existing shareholders
- Private placement of non-exercised subscription rights after the subscription period

**Subscription ratio** 

• 1 new share per 6 subscription rights (represented by coupon nr. 25 for the Ordinary Shares, coupon nr. 14 for the Preferential Shares 1 and coupon nr. 13 for the Preferential Shares 2)

**Subscription price** 

• €95 per new share

**Subscription period** 

- Subscription period with preferential subscription rights: 22 April 2015 (9am) 6 May 2015 (4pm)
- Private placement of scrips (non-exercised rights): 7 or 8 May 2015

Dividend

- The New Shares will be entitled to the dividend of the current financial year (started on 1 January 2015) pro rata temporis as from the Closing Date until 31 December 2015. The New Shares will therefore be issued:
  - o ex-coupon n° 26, i.e. the coupon representing the right to a dividend for the financial year which closed on 31 December 2014; and
  - o ex-coupon n° 27, i.e. the coupon representing the right to a dividend for the current financial year (started on 1 January 2015) until the day before the issue date of the New Shares.

Payment & settlement

• Payment, delivery and listing of the new shares: 12 May 2015

**Syndicate** 

- Global Coordinator: BNP Paribas Fortis and KBC Securities
- Joint Bookrunners: BNP Paribas Fortis, ING and KBC Securities
- Co-lead Managers: Belfius Bank, Degroof Bank, Kempen & Co, Joh.Berenberg/Gossler

# **96. TRANSACTION DETAILS: TIMETABLE**

EVENT	DATE
Board meeting deciding rights issue terms and pricing	20.04.2015
Announcement of rights issue terms	21.04.2015
Detachment of the 3 coupons:	21.04.2015
<ul> <li>preferential subscription rights (for Ordinary and Preferential Shares)</li> </ul>	
2014 dividend	
pro rata 2015 dividend	
Subscription period for existing shareholders	
Trading of the preferential rights of the Ordinary Shares on Euronext	
Brussels.	22.04.2015 to 06.05.2015 (included)
Preferential Rights relating to the Preferential Shares will not be	22.04.2013 to 00.03.2013 (included)
admitted to trading on any stock exchange. They may however be	
transferred over the counter.	
Announcement of the results of the rights offering	07.05.2015 or 08.05.2015
Scrip placement of the unexercised preferential rights to institutional	07.05.2015 or 08.05.2015
investors through an accelerated bookbuilding	
	07.05.2015 (after market closing) or
Announcement of the results of the scrip placement	08.05.2015
Results of the Offering	08.05.2015
Settlement and listing of new shares	12.05.2015




# 7. OUTLOOK

- Sustainable earnings and high dividend yield
- 65% of 2015 operating result from alternative assets,
   35% from offices
  - 2015 cost of debt significantly < 3%</li>
    - Long-term debt ratio goal < 50%</li>

Gross dividend yield\*

	Actual 2014	2015 Forecast published in February 2015	2015 Forecast after rights issue
EPS	€6.70	€6.85	€5.93
DPS	€5.50	€5.50	€5.50
Pay-out			
ratio	82.1%	80.3%	92.7%
Debt ratio	48.1%	48.6%	41.7%





# 98. Q&A






## **PAPPENDIX: THE COFINIMMO SHARE**





- Market cap: €1.9 billion at 31.03.2015
- Number of shares: [18,025,908] 100% free float
- Major indexes: Bel20, EPRA Europe, **GPR 250**
- M€3 traded daily on average Velocity: 49%

#### Shareholders at 31.03.2015





# **PAPPENDIX: CAPITALIZATION & INDEBTEDNESS**

In M€:	31.03.2015
Shareholders' equity	1,612.6
Shareholders' equity attributable to shareholde	rs of the parent company 1,544.5
Capital	963.1
Share premium account	384.0

Share premium account	384.0
Reserves	202.7
Net result of the financial year	-5.3
Net current result - excluding IAS 39 impact	30.6
IAS 39 impact	-29.6
Result on the portfolio	-6.3
Minority interests	68,1

	31.03.2015
Liabilities	1,900.0
Non-current liabilities	1,434.2
Provisions	18.4
Non-current financial debts	1,296.4
Other non-current financial liabilities	83.7
Deferred taxes	35.7
Current liabilities	465.8
Current financial debts	328.5
Other current financial liabilities	28.9
Trade debts and other current debts	76.2
Accrued charges and deferred income	32.2



# **PAPPENDIX: INCOME STATEMENT**

A. NET CURRENT RESULT	31.12.2014	31.12.2013
Rental income, net of rental-related		
expenses	195,827	195,185
Writeback of lease payments sold and	15.024	25.276
discounted (non-cash)	15,931	25,276
Taxes and charges on rented properties not	-2,756	-2,376
recovered	-2,730	-2,370
Redecoration costs, net of tenant	-928	-1,176
compensation for damages	-320	-1,170
Property result	208,074	216,909
Technical costs	-3,802	-5,114
Commercial costs	-1,137	-956
Taxes and charges on unlet properties	-3,922	-4,075
Property result after direct property costs	199,213	206,764
Property management costs	-14,295	-14,258
Property operating result	184,918	192,506
Corporate management costs	-7,176	-6,887
Operating result before result on the	177,742	185,619
portfolio	177,742	103,013
Financial income (IAS 39 excluded)	5,577	5,723
Financial charges (IAS 39 excluded)	-57,009	-66,972
Revaluation of derivative financial	-	-13,686
instruments (IAS 39)	136,143	-13,000
Share in the result of associated companies	1,180	1,425
and joint ventures	1,100	1,425
Taxes	-2,493	-2,179
Net current result	-11,146	109,930
Minority interests	-4,509	-5,006
Net current result – Group share	-15,655	104,924

B. RESULT ON THE PORTFOLIO	31.12.2014	31.12.2013
Gains or losses on disposals of investment properties and other non-financial assets	-22,441	147
Changes in the fair value of investment properties	-5,455	-26,260
Share in the result of associated companies and joint ventures	127	112
Other result on the portfolio	-10,378	-22,065
Result on the portfolio	-38,147	-48,066
Minority interests	1,131	1,879
Result on the portfolio – Group share	-37,016	-46,187

C. NET RESULT	31.12.2014	31.12.2013
Net result	-49,293	61,864
Minority interests	-3,378	-3,127
Net result – Group share	-52,671	58,737



# **PAPPENDIX: BALANCE SHEET**

	31.12.2014	31.12.2013
Non-current assets	3,410,050	3,565,180
Goodwill	118,356	129,356
Intangible assets	659	753
Investment properties	3,195,773	3,338,709
Other tangible assets	411	677
Non-current financial assets	10,933	20,941
Finance lease receivables	78,018	67,449
Trade receivables and other non- current assets	38	40
Participations in associated companies and joint ventures	5,862	7,255
Current assets	88,962	105,263
Assets held for sale	3,410	8,300
Current financial assets	498	2,782
Finance lease receivables	1,618	1,236
Trade receivables	24,781	25,698
Tax receivables and other current assets	17,505	24,304
Cash and cash equivalents	17,117	15,969
Accrued charges and deferred income	24,033	26,974
TOTAL ASSETS	3,499,012	3,670,443

	31.12.2014	31.12.2013
Shareholders' equity Shareholders' equity attributable to	1,608,965	1,681,462
shareholders of the parent company	1,541,971	1,614,937
Capital	963,067	942,825
Share premium account	384,013	372,110
Reserves	247,562	241,265
Net result of the financial year	-52,671	58,737
Minority interests	66,994	66,525
Liabilities	1,890,047	1,988,981
Non-current liabilities	1,303,250	1,412,904
Provisions	17,658	18,180
Non-current financial debts	1,148,023	1,266,665
Other non-current financial liabilities	102,041	93,304
Deferred taxes	35,528	34,755
Current liabilities	586,797	576,077
Current financial debts	473,499	455,509
Other current financial liabilities	24,698	21,921
Trade debts and other current debts	59,850	64,680
Accrued charges and deferred income	28,750	33,967
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES	3,499,012	3,670,443



# **PDISCLAIMER**

This presentation is not for distribution, directly or indirectly, in or into the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"), Australia, Canada or Japan. This presentation does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to acquire, any securities in the United States or any jurisdiction in which such an offer or solicitation is unlawful. The securities of Cofinimmo SA/NV have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or with any securities regulatory authority of any state or other jurisdiction of the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. No public offering of the securities is being made into the United States.

An investment in shares involves risks.

An investor is exposed to and accepts the risk of losing all or part of his invested capital.

